SCHEMBL1470265

SCHEMBL1470265

CC(F)C[C](F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5943350 0.73
SCHEMBL15403900 0.73
SCHEMBL21561430 0.71
SCHEMBL10049096 0.71
SCHEMBL1470134 0.69
SCHEMBL29130149 0.69
SCHEMBL1030811 0.67
SCHEMBL1469466 0.67
SCHEMBL1030810 0.67
SCHEMBL10346482 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230390303-A1 CANCER TREATMENT BY COMBINATION OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR ONO PHARMACEUTICAL CO., LTD. (JP) 2023-12-07 US disclosed
EP-4245301-A1 CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR ONO Pharmaceutical Co., Ltd. (JP) 2023-09-20 EP disclosed
US-20220048881-A1 TRICYCLIC SPIRO COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2022-02-17 US disclosed
US-11192876-B2 Tricyclic spiro compound ONO PHARMACEUTICAL CO., LTD. (JP) 2021-12-07 US disclosed
EP-3482760-B1 COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR ONO PHARMACEUTICAL CO (JP) 2021-11-10 EP disclosed
US-11065226-B2 Combination comprising EP4 antagonist and immune checkpoint inhibitor ONO PHARMACEUTICAL CO., LTD. (JP) 2021-07-20 US disclosed
EP-3778562-A1 TRICYCLIC SPIRO COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2021-02-17 EP disclosed
US-20200102284-A1 TRICYCLIC SPIRO COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2020-04-02 US disclosed
US-10538502-B2 Tricyclic spiro compound ONO PHARMACEUTICAL CO., LTD. (JP) 2020-01-21 US disclosed
US-20190255013-A1 COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR ONO PHARMACEUTICAL CO., LTD. (JP) 2019-08-22 US disclosed
CN-102208681-A Nonaqueous electrolyte solution and lithium secondary battery using same MITSUBISHI CHEM CORP 2011-10-05 CN disclosed
US-8007938-B2 Nonaqueous electrolyte solution and lithium secondary battery using same MITSUBISHI CHEMICAL CORPORATION (JP) 2011-08-30 US disclosed
CN-101609911-B Nonaqueous electrolyte solution and lithium secondary battery using same MITSUBISHI CHEM CORP 2011-05-18 CN disclosed
US-20110070485-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2011-03-24 US disclosed
CN-101894973-A Nonaqueous electrolyte solution and lithium secondary battery using same MITSUBISHI CHEM CORP 2010-11-24 CN disclosed
CN-101609911-A Nonaqueous electrolyte solution and lithium secondary battery using same MITSUBISHI CHEM CORP (JP) 2009-12-23 CN disclosed
CN-100544109-C Nonaqueous electrolyte solution and lithium secondary battery using same MITSUBISHI CHEM CORP (JP) 2009-09-23 CN disclosed
US-20070224514-A1 Nonaqueous Electrolyte Solution and Lithium Secondary Battery Using Same MITSUBISHI CHEMICAL CORPORATION (JP) 2007-09-27 US disclosed
CN-1943071-A Nonaqueous electrolyte solution and lithium secondary battery using same MITSUBISHI CHEM CORP (JP) 2007-04-04 CN disclosed
EP-1744394-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2007-01-17 EP disclosed